1-piperidinocyclohexanecarbonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Piperidinocyclohexanecarbonitrile is a **chemical compound**, often abbreviated as **PCCN**, with the chemical formula **C₁₂H₂₀N₂**. It is a **heterocyclic compound** containing both a **piperidine ring** and a **cyclohexane ring**.

**Why is it important for research?**

1-Piperidinocyclohexanecarbonitrile has gained interest in research for various reasons:

* **Pharmacological Activity:** It has shown **pharmacological activity** in several areas. For example, it has been investigated as a potential **antidepressant** due to its effects on serotonin reuptake.
* **Synthesis and Chemical Reactions:** It is a useful **intermediate** in organic synthesis, allowing for the creation of various other compounds with potentially interesting properties.
* **Chemical Reactivity:** Its structure allows for various chemical reactions, making it a valuable tool for studying **chemical reactivity** and **reaction mechanisms**.
* **Materials Science:** Its potential as a **precursor** for various polymers and materials is also being explored.

**Specific Examples of Research:**

* Studies have shown that PCCN can **inhibit the reuptake of serotonin**, a neurotransmitter associated with mood regulation, suggesting potential applications in the treatment of depression.
* Research has explored its use in the synthesis of **new pharmaceuticals**, including those targeting neurodegenerative diseases.
* Its reactivity allows for the development of new synthetic methods and the study of fundamental chemical principles.

**However, it's important to note:**

* **Toxicity:** As with many chemical compounds, PCCN may exhibit toxicity, and its use should be handled with appropriate safety precautions.
* **Limited Clinical Data:** While research shows promise, further studies are needed to fully understand its safety and efficacy in humans.

Overall, 1-Piperidinocyclohexanecarbonitrile is a compound with potential applications in various fields, including pharmaceuticals, materials science, and chemical research. Its unique structure and properties make it a valuable subject for ongoing research.

1-piperidinocyclohexanecarbonitrile: intermediate in the chemical synthesis of phencyclidine; imperfectly synthesized PCP correlated with undue toxic effects; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	62529
SCHEMBL ID	1742367
MeSH ID	M0058678

Synonyms (44)

Synonym
5-20-03-00060 (beilstein handbook reference)
03zi7zzw5q ,
unii-03zi7zzw5q
ENAMINE_001251 ,
dea no. 8603
nsc 97072
1-(1-piperidinyl)cyclohexanecarbonitrile
brn 0134530
1-(1-cyanocyclohexyl)piperidine
piperidinocyclohexanecarbonitrile
nsc97072
cyclohexanecarbonitrile, 1-(1-piperidinyl)-
1-piperidinocyclohexanecarbonitrile
nsc-97072
wln: t6ntj a- al6tj acn
3867-15-0
cyclohexanecarbonitrile, 1-piperidino-
DB01539
NCGC00160487-01
STK500616
1-(piperidin-1-yl)cyclohexanecarbonitrile
wwsaykjwuzjlrt-uhfffaoysa-
inchi=1/c12h20n2/c13-11-12(7-3-1-4-8-12)14-9-5-2-6-10-14/h1-10h2
HMS1397I19
1-piperidin-1-ylcyclohexane-1-carbonitrile
AKOS000638043
1-(piperidin-1-yl)cyclohexane-1-carbonitrile
dtxcid9026184
dtxsid1046184 ,
cas-3867-15-0
tox21_111849
FT-0679016
1-piperidin-1-ylcyclohexanecarbonitrile
1-piperidinocyclohexanecarbonitrile ( precursors to phencyclidine (pcp))
SCHEMBL1742367
1-piperidin-1-yl-cyclohexanecarbonitrile
1-(1-piperidinyl)cyclohexanecarbonitrile #
mfcd00179761
AF-962/00511053
F0896-0065
Q27092788
1-piperidine cyclohexane carbonitrile
LS-01648
?1-piperidinocyclohexanecarbonitrile

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	7 (50.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (42.86)	24.3611
2020's	1 (7.14)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	21.16 (24.57)
Research Supply Index	2.83 (2.92)
Research Growth Index	4.70 (4.65)
Search Engine Demand Index	18.60 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (21.16)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	1.95	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
thiosulfates Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.. thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.	1.95	1	divalent inorganic anion; sulfur oxide; sulfur oxoanion	human metabolite
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	1.97	1	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
cyanides Cyanides: Inorganic salts of HYDROGEN CYANIDE containing the -CN radical. The concept also includes isocyanides. It is distinguished from NITRILES, which denotes organic compounds containing the -CN radical.. cyanides : Salts and C-organyl derivatives of hydrogen cyanide, HC#N.. isocyanide : The isomer HN(+)#C(-) of hydrocyanic acid, HC#N, and its hydrocarbyl derivatives RNC (RN(+)#C(-)).. cyanide : A pseudohalide anion that is the conjugate base of hydrogen cyanide.	1.95	1	pseudohalide anion	EC 1.9.3.1 (cytochrome c oxidase) inhibitor
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	3.68	10	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
picric acid picric acid: used as antiseptic, astringent & stimulant for epitheliazation; structure. picric acid : A C-nitro compound comprising phenol having three nitro substtituents at the 2-, 4- and 6-positions.	1.96	1	C-nitro compound	antiseptic drug; explosive; fixative
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	1.97	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
chlorophyll a Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.	2.05	1	chlorophyll; methyl ester	cofactor
glycolipids [no description available]	2.08	1
piperidines Piperidines: A family of hexahydropyridines.	3.21	6
sulfoquinovosyl diglyceride [no description available]	2.08	1
pheophytin a pheophytin a: structure given in first source; RN given refers to (3S-(3alpha(2E,7S,11S),4beta,21beta))-isomer	2.05	1

Condition	Relationship Strength	Studies
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Pheochromocytoma, Extra-Adrenal [description not available]	2.05	1
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	2.05	1
Angel Dust Abuse [description not available]	1.96	1
Tachyarrhythmia [description not available]	1.96	1
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	1.96	1
Acute Liver Injury, Drug-Induced [description not available]	1.95	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.95	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	1.95	1

chemdatabank.com